IMC003

"IMC003" is a code name used by multiple pharmaceutical companies for distinct investigational drug candidates. For instance, ImmuneOncia Therapeutics is developing an IMC-003 as a LAG3 inhibitor for neoplasms, currently in preclinical development. Shenzhen Immuno Cure Biomedical Co., Ltd. also has an IMC-003, which is a PD-1 inhibitor, for neoplasms like mesothelioma, also in preclinical stages. Additionally, ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is developing IMC-003/IMM72, an activin receptor type IIA-Fc fusion protein, for pulmonary arterial hypertension (PAH), which has an accepted clinical trial application in China and is in Phase I for healthy postmenopausal women. Immunofoco Biotech is also developing an IMC-003 for neoplasms and digestive system disorders, which is in preclinical development. Due to these multiple distinct drug candidates sharing the same code name, "IMC003" is a non-specific identifier.